Please assess the completion status of the following clinical trial:

Trial Title: STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duration of mechanical ventilation \> 48 h~* First episode of suspicion of VAP with a Clinical Pulmonary Infection Score modified ≥ 5~* BAL, plugged telescopic catheter and/or tracheal aspirates quantitative cultures performed prior administration of antibiotics~* Informed consent~Exclusion Criteria:~* Statin treatment received under mechanical ventilation~* Age less than 18 years~* Pregnancy~* Unable to receive or unlikely to absorb enteral study drug~* Patient, surrogate, or physician not committed to full support ).~* Moribund patient with a SAPS II score \> 75~* Simvastatin specific exclusions Allergy or intolerance to statins Physician insistence for the use or avoidance of statins during the current hospitalization CK , ALT or AST \> 5 times the upper limit of normal Receiving cyclosporine, gemfibrozil, lopinavir, ritonavir itraconazole, kétoconazole, érythromycine, clarithromycine, télithromycine, néfazodone, verapamil, diltiazem~* Severe chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLACEBO (Type: PLACEBO_COMPARATOR): Half of the patients will be randomized to the placebo
- Simvastatin (Type: ACTIVE_COMPARATOR): Half of the subjects will receive the active drug, Simvastatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).